SAB Biotherapeutics (SABS) Receivables (2020 - 2023)

SAB Biotherapeutics has reported Receivables for 4 years, with the latest figure at $364117.0 in Q2 2023.

• For the quarter ending Q2 2023, Receivables fell 96.21% year-over-year to $364117.0; the trailing twelve-month figure through Jun 2023 stood at $364117.0 (down 96.21% YoY), and the FY2022 full-year result was $5.6 million, down 30.69% from the prior year.
• Receivables for Q2 2023 stood at $364117.0, down from $763123.0 in the prior quarter.
• The five-year high for Receivables was $20.6 million in Q4 2020, with the low at $364117.0 in Q2 2023.
• Historically, Receivables has averaged $8.7 million across 4 years, with a median of $8.8 million in 2021.
• Annual changes were most pronounced in 2022 — Receivables sank 30.69% — and 2023, when it tumbled 96.21%.
• SAB Biotherapeutics' Receivables stood at $20.6 million in 2020, then plunged by 61.04% to $8.0 million in 2021, then slumped by 30.69% to $5.6 million in 2022, then tumbled by 93.45% to $364117.0 in 2023.
• The last three Receivables figures came in at $364117.0 (Q2 2023), $763123.0 (Q1 2023), and $5.6 million (Q4 2022), per Business Quant data.